Table 1 Patient characteristics
|  | ND-CAD (n = 27) | D-CAD (n = 20) | p-value |
|---|---|---|---|
Age (year) | 68.7 ± 1.6 | 69.2 ± 1.9 | 0.8 |
Gender (male/female) | 24/3 | 13/7 | Â |
Metabolic profile | |||
 BMI (kg/m2) | 29.3 ± 0.9 | 33.9 ± 1.1 | 0.002** |
 Diabetic duration (years) | – | 11.3 ± 1.7 |  |
 HbA1c (mmol/mol) | 37.1 ± 0.7 | 55.3 ± 2.5 |  < 0.001*** |
Hemodynamic profile | |||
 MAP (mm Hg) | 95.0 ±  2.6 | 95.9± 2.6 | 0.81 |
 LVEDV (mL) | 102.0 ±  7.9 | 106.8 ± 9.9 | 0.74 |
 LVESV (mL) | 47.6 ±  5.7 | 59.0 ± 8.5 | 0.29 |
 HR (beats/min) | 73.9 ±  4.2 | 71.7 ± 2.6 | 0.68 |
 SV (mL) | 54.4 ±  3.0 | 47.7 ± 3.2 | 0.22 |
 CO (L/min) | 4.0 ±  0.4 | 3.5 ± 0.2 | 0.4 |
Diastolic profile | |||
 E/A | 1.0 ± 0.1 | 0.7 ± 0.05 | 0.03* |
 E/e’ | 11.6 ± 0.7 | 13.1 ± 1.0 | 0.21 |
 decT (msec) | 245.8 ± 11.9 | 271.8 ± 19.8 | 0.24 |
Systolic profile | |||
 Ejection fraction (%) | 55.3 ± 1.8 | 49.1 ± 2.0 | 0.027* |
 Fractional shortening (%) | 30.6 ± 1.2 | 30.3 ± 2.6 | 0.93 |
Ventricular structure | |||
 IVSd (cm) | 1.2 ± 0.1 | 1.3 ± 0.1 | 0.56 |
 LVPWd (cm) | 1.1 ± 0.04 | 1.0 ± 0.1 | 0.66 |
 LVIDd (cm) | 4.6 ± 0.1 | 4.9 ± 0.2 | 0.21 |
 LVIDs (cm) | 3.2 ± 0.1 | 3.4 ± 0.2 | 0.34 |
Medications | |||
 Statins | 21/27 (77.8%) | 18/20 (90.0%) |  |
 Beta-blockers | 20/27 (74.1%) | 15/20 (75.0%) |  |
 ACE inhibitors | 11/27 (40.7%) | 12/20 (60.0%) |  |
 Calcium channel blockers | 3/27 (11.1%) | 14/20 (70.0%) |  |
 Anti-diabetic agents | 0/27 (0%) | 16/20 (80.0%) |  |
  Insulin | – | 5/16 (31.3%) |  |
  Metformin | – | 5/16 (31.3%) |  |
  Sulfonylurea | – | 1/16 (6.3%) |  |
  Insulin and metformin | – | 4/16 (25.0%) |  |
  Metformin and sulfonylurea | – | 1/16 (6.3%) |  |